November 19, 2025 5:09pm

Although, today’s tin could be tomorrow’s gold

AS the VIX closed at 23.81 after Tuesday’s 24.67, Monday’s 22.73 and Friday’s 19.83

Pre-open Indication Scoring: 1 Hit and 6 Miss

RMi collects, interprets and disseminates cell and gene therapy sector (C&GT) fact-based news, trusted and verified intel and share pricing data to bridge the gap to an investment decision

Never leave an investor uninformed!  

 

The past, present and future values of RMi’s analysis sheds light on the cell and gene therapy’s (C&GT) sector’s “current” acrobatics 

Wednesday’s RMi Pre-opening Bell: Reassurance … https://www.regmedinvestors.com/articles/14202

RMi Research Note: Harvard Apparatus GT (OTCQB): Broke … https://www.regmedinvestors.com/articles/13812

The peril facing the cell and gene therapy (C&GT) sector’s share pricing isn’t just applications of macro or even micro econs, sentiment or algorithms within electronic trading; it’s losing highly reliable, accurate and transparent data.

 

Wednesday: The Dow closed UP +47.03 points or +0.10%, the S&P closed UP +24.84 points or +0.38% while the Nasdaq closed UP +131.383 points or +0.59%

  • Theme of the session: concerns about "tech's" massive spending on the AI buildout has caused multi-day declines, as fund investors dump holdings

Wednesday’s (my) 40-company covered sector’s advance/decline line opened negative with 13 incliners, 24 decliners and 3 flats ending with a negative close of 10 incliners, 27 decliners and 3 flats

  • The Nasdaq led the way on a recovery, the S&P 500 put up while the Dow climbed.

Henry’omics: We need to more than consider the macro-economic environment to comprehend the micro re “our” universe of cell and gene therapy (C&GT) sector

  • Fed minutes released Wednesday were put under the microscope for insight into the economy and future policy. Those minutes showed the kind of division over December's cut that has been on public display over the last several weeks.
  • Investors' view of the Fed's next move could shift on Thursday, when the market gets the September jobs report — the first major data release since the government shutdown delayed economic updates.

Metrics:  Wednesday …

  • The RUT was down -0.84 points or -0.04%,
  • The IWM was down -0.04 or -0.02%;
  • The IBB was down -1.25 points or -0.75%,
  • The NBI was down -51.71 points or -0.92%;
  • The XLV was down -0.88 points or -3.57%,
  • The XBI was down -0.68 points or -0.59% … while
  • The VIX was down -0.88 points or -3.57% at to 23.81

 

Q4 – November - 3 positive and 10 negative closes

  • October -1 neutral, 11 positive and 12 negative closes

 

Wednesday Closing UP (10 of 10)

  • AxoGen (AXGN +$1.27 after Tuesday’s +$0.44),
  • Lenz Therapeutics (LENZ +$1.19 after Tuesday’s +$1.53 after Monday’s +$0.10),
  • Supernus Therapeutics (SUPN +$0.80 after Tuesday’s -$0.19),
  • IQVIA Holdings (IQV +$0.41 after Tuesday’s +$1.16 after Monday’s -$4.47),
  • BioLife Solutions (BLFS +$0.37),
  • Cellectis SA (CLLS +$0.275),
  • Prime Medicine (PRME +$0.16 after Tuesday’s -$0.225 after Monday’s +$0.437),
  • Capricor Therapeutics (CAPR +$0.14),
  • Fate Therapeutics (FATE +$0.035),
  • Solid Biosciences (SLDB +$0.005),

Flat (3)

  • Adverum Biotechnologies (ADVM)
  • Brainstorm Cell Therapeutics (BCLI)
  • Harvard Apparatus RT (OTCQB: HRGN) $0.00 after Tuesday’s $0.00, Monday’s $0.00, Friday’s -$0.010 (with 3800 shares traded), Thursday’s $0.00, Wednesday’s -$0.01, Tuesday’s $0.00 and last Monday’s $0.00)

Wednesday’s Closing DOWN (10 of 27):

Wednesday’s Closing DOWN (10 of 27):

  • Vertex (VRTX -$14.65 after Tuesday’s +$1.50 after Monday’s -$3.13),
  • CRISPR Therapeutics (CRSP -$2.76 after Tuesday’s -$1.85 and Monday’s +$2.79),
  • uniQure NV (QURE -$1.81 after Tuesday’s -$0.62 and Monday’s +$0.45),
  • Alnylam Pharmaceuticals (ALNY -$1.52 after Tuesday’s +$1.76 and Monday’s +$11.38),
  • Arrowhead Pharma (ARWR -$1.51 after Tuesday’s +$0.32 and Monday’s -$1.11),
  • BioNTech (BNTX -$1.12 after Tuesday’s +$0.14 and Monday’s -$0.42),
  • Sarepta Therapeutics (SRPT -$1.05),
  • Ultragenyx Pharmaceuticals (RARE -$0.96 after Tuesday’s +$0.29 and Monday’s -$0.54),
  • Beam Therapeutics (BEAM -$0.93 after Tuesday’s -$0.10 and Monday’s +$0.30),
  • Moderna (MRNA -$0.74),

 

The Bottom Line: More of the … WHYs

The C&GT sector extended their losses again on Wednesday, Tuesday … with the C&GT sector equities getting “lapped” in the A/D (advance/decline) Line.

C&GT sector equities continue to level share pricing as Q3 earnings release

I have seen share pricing interruption … from earnings expectation and consensus always considering earnings season LPS (loss-per-share).

  • Think about it; one of the biggest problems with the cell and gene therapy sector’s share pricing is …  99% of them have no earnings! Revenue from collaborations and runways have become indications of sustainability.
  • I believe earnings per share (EPS) estimates need to be revised along with the response to their share pricing declines upon their release to shake-off pipeline uncertainties
  • Meeting earnings expectation and/or missing consensus will deem share pricing outcomes
  • As earnings evolve, I think it's important to focus on fundamentals, advancing clinical catalysts, “runways” and sector company’s capacity/ability to finance

As the leading voice of cell and gene therapy investors; I am NOT always a doom and gloom analyst/journalist but a man who has been “there” (BUY, SELL, VC and multiple operating roles) with the gray hair and a readership following with real numbers to prove it!

A real question, are cell and gene therapy (C&GT) sector companies with high insider ownership present … opportunity?

  • Do they often demonstrate alignment between management and shareholder interests … a critical factor in navigating volatile market conditions?
  • I will be looking into this …! Stay tuned.

 

November: understand the “flow” …

New week:

  • 11/19 – Wednesday closed negative with 10 positive, 27 negative and 3 flats
  • 11/18 – Tuesday closed negative with 18 positive, 21 negative and 1 flat
  • 11/17 – Monday closed negative with 19 positive, 20 negative and 1 flat

Last week:

  • 11/14 - Friday closed negative with 19 positive, 21 negative and 0 flats
  • 11/13 – Thursday closed negative with 8 positive, 32 negative and 0 flat
  • 11/12 – Wednesday closed negative with 18 positive, 22 negative and 0 flat
  • 11/11 – Tuesday closed positive with 34 positive, 4 negative and 2 flats
  • 11/10 - Monday closed positive with 26 positive, 14 negative and 0 flats

 

Welcome to my world of defining the “grey’ in our universe!

  • I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.
  • “I hate to be so negative or contrarian but, this is a NO spin zone and truth is its product; I can always be WRONG but, I am mostly EARLY!”

 

Why do I keep repeating, framed in a different para, so investors can make the connection

The top three (3) performing in the session:   

  • Wednesday: AxoGen (AXGN), Lenz Therapeutics (LENZ) and Supernus Therapeutics (SUPN)
  • Tuesday: Alnylam Pharmaceuticals (ALNY), Lenz Therapeutics (LENZ) and Vertex (VRTX)
  • Monday: Alnylam Pharmaceuticals (ALNY), CRISPR Therapeutics (CRSP) and Ionis Pharmaceuticals (IONS)
  • Friday: Vertex (VRTX), Ionis Pharmaceuticals (IONS) and CRISPR Therapeutics (CRSP)

The worst three (3) in the session:

  • Wednesday: Vertex (VRTX), CRISPR Therapeutics (CRSP) and uniQure NV (QURE)
  • Tuesday: CRISPR Therapeutics (CRSP), uniQure NV (QURE) and Vericel (VCEL)
  • Monday: IQVIA Holdings (IQV), Vertex (VRTX) and Vertex (VRTX)
  • Friday: Alnylam Pharmaceuticals (ALNY), IQVIA Holdings (IQV) and BioLife Solutions (BLFS)

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad, or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor, and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication. Regulation Analyst Certification (Reg AC):

The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.